Papers - FUJIHARA Kazuo
-
The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese.
Yamazaki N, Misu T, Matsumoto Y, Takai Y, Namatame C, Ono H, Kaneko K, Nishiyama S, Kuroda H, Takahashi T, Nakashima I, Fujihara K, Aoki M
Mult Scler Relat Disord 92 106176 2024.12
-
Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan.
Niino M, Isobe N, Araki M, Ohashi T, Okamoto T, Ogino M, Okuno T, Ochi H, Kawachi I, Shimizu Y, Takahashi K, Takeuchi H, Tahara M, Chihara N, Nakashima I, Fukaura H, Misu T, Miyazaki Y, Miyamoto K, Mori M, Kinoshita M, Takai Y, Fujii C, Watanabe M, Fujihara K
Mult Scler Relat Disord 90 105829 2024.10
-
Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance.
Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Tsumuraya T, Yamashita K, Nakahara J, Nakashima I, Fujihara K
Neurol Ther 13 ( 5 ) 1361 - 1383 2024.10
-
Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+NMOSD.
Kaneko K, Kuroda H, Matsumoto Y, Sakamoto N, Yamazaki N, Yamamoto N, Umezawa S, Namatame C, Ono H, Takai Y, Takahashi T, Fujimori J, Nakashima I, Harigaya Y, Lassmann H, Fujihara K, Misu T, Aoki M
Neurol Neuroimmunol Neuroinflamm 11 ( 5 ) e200293 2024.9
-
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium.
J Neurol 271 ( 8 ) 4794 - 4812 2024.8
-
Humanized-aquaporin-4-expressing rat created by gene-editing technology and its use to clarify the pathology of neuromyelitis optica spectrum disorder.
Namatame C, Abe Y, Miyasaka Y, Takai Y, Matsumoto Y, Takahashi T, Mashimo T, Misu T, Fujihara K, Yasui M, Aoki M
Int J Mol Sci 25 ( 15 ) 8169 2024.7
-
Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets.
Khodaie F, Mohamadi M, Ebrahimi Y, Sahraian MA, Moghadasi AN, Ayoubi S, Goudarzi H, Paybast S, Kamyari N, Asgari N, Fujihara K, Heidari H, Eskandarieh S
Mult Scler Relat Disord 87 105685 2024.7
-
Safety and efficacy of inebilizumab in patients with neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree AC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL, on behalf of the N-MOmentum study investigators.
Lancet Neurol 23 ( 6 ) 588 - 602 2024.6
-
Stochastic models for the development and disease course of multiple sclerosis.
Akaishi T, Misu T, Takahashi T, Fujihara K, Fujimori J, Nakashima I, Aoki M
Clin Neurol Neurosurg 239 108224 2024.4
-
Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K
Mult Scler Relat Disord 84 105502 2024.4
-
Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: a Japanese nationwide administrative data study.
Matsumoto Y, Tarasawa K, Misu T, Namatame C, Takai Y, Kuroda K, Fujihara K, Fushimi K, Fujimori K, Aoki M.
Mult Scler Relat Disord 81 105349 2024.1
-
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes M, Weinshenker B, Yamout B, Fujihara K
Lancet Neurol 23 ( 10 ) 1035 - 1049 2024.1
-
Myelin oligodendrocyte glycoprotein antibody-associated disorders: an overview.
Misu T, Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Ono H, Namatame C, Nishiyama S, Fujimori J, Kuroda H, Nakashima I, Fujihara K, Aoki M.
Clin Exp Neuroimmunol. 2023.12
-
Microfibrillar-associated protein 4 as potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: pathological and clinical aspects.
Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Friedeman Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N.
Mult Scler. 29 ( 14 ) 1721 - 1735 2023.10
-
Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, Misu T, Fujihara K, Aoki M.
Brain. 146 ( 9 ) 3938 - 3948 2023.9
-
Epidemiology of MOGAD: A review of prevalence and incidence worldwide.
Hor JY, Fujihara K.
Front Neurol. 15 ( 14 ) 1260358 2023.9
-
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigators.
J Neurol Neurosurg Psychiatry. 94 ( 9 ) 757 - 768 2023.9
-
Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K, Kim HJ, Saida T, Misu T, Nagano Y, Totsuka N, Iizuka M, Kido S, Terata R, Okumura K, Hirota S, Cree BAC.
Mult Scler Relat Disord. 79 104938 2023.8
-
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W, Waubant EL, Yamout B, Cohen JA.
Lancet Neurol. 22 ( 8 ) 750 - 768 2023.8
-
Associations between neuromyelitis optica spectrum disorder, Sjogren's ¨ syndrome, and conditions with electrolyte disturbances.
Akaishi T, Tarasawa K, Matsumoto Y, Sandhya P, Misu T, Fushimie K, Takahashi T, Fujimori J, Ishii T, Fujimori K, Yaegashi N, Nakashima I, Fujihara K, Aoki M.
J Neurol Sci. 452 120742 2023.7
-
Time-Dependent Analysis of Sicca Symptoms and Anti-Ro/SSA and Anti-La/SSB Antibodies in Patients with AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T, Takahashi T, Misu T, Fujihara K, Nakashima I, Aoki M.
Tohoku J Exp Med. 260 ( 3 ) 215 - 221 2023.7
-
Pathology of MOGAD: a comparison with MS and AQP4 antibody-positive NMOSD.
Takai Y, Misu T, Fujihara K, Aoki M.
Front Neurol. 21 ( 14 ) 1209749 2023.7
-
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Motalban X, Shi FD, Tintore M, Xue Q, Yang C, Zhou H.
Ther Adv Neurol Disord. 14 ( 16 ) 2023.7
-
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.
Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K.
Ther Adv Neurol Disord. 16 2023.6
-
Attack adjudication in neuromyelitis optica spectrum disorder: substantiation of criteria by magnetic resonance imaging and biomarkers in N-Momentum.
Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigator.
Mult Scler. 29 ( 8 ) 945 - 955 2023.6
-
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Seze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto MA, Law L, Leite IS, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A.
Neurol Neuroimmunol Neuroinflamm. 10 ( 4 ) e200124 - e200124 2023.5
-
White blood cell count profiles in the acute phase of AQP4-IgG seropositive NMOSD and MOG-IgG-associated disease.
Akaishi T, Misu T, Fujihara K, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Kaneko K, Takahashi T, Fujimori J, Takai Y, Nishiyama S, Ishii T, Aoki M, Nakashima I, Hozawa A.
Sci Rep. 13 ( 1 ) 6481 - 6481 2023.4
-
Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): International MOGAD Panel Proposed Criteria.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan E, Ramanathan S, Waters P, Tenembaum S, MD, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock S, Fujihara K, Palace J.
Lancet Neurol. 22 ( 3 ) 268 - 282 2023.3
-
Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images.
Tomura N, Saginoya T, Sanpei T, Konno T, Fujihara K.
Acta Radiol 64 ( 2 ) 719 - 724 2023.2
-
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Bennett JL, Fujihara K, Kim HJ, Marignier R, O’Connor KC, Sergott RC, Traboulsee A, Wiendl H, Wuerfel J, Zamvil SS, Anania VG, Buffels R, Künzel T, Lekkerkerker AN, Lennon-Chrimes S, Pittock SJ.
Front Neurol. 17 ( 14 ) 1114667 2023.2
-
A novel association of osmotic demyelination in Sjogren’s syndrome ¨ prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review.
Sandhya P, Akaishi T, Fujihara K, Aoki M.
Mult Scler Relat Disord. 69 104466 2023.1
-
Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, von Büdingen HC, Klingelschmitt G, Stokmaier D, Bennett JL.
Neurol Neuroimmunol Neuroinflamm. 10 ( 1 ) e200071 2022.12
-
Diagnosis and classification of optic neuritis.
Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov M, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi P, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, DeSeze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Froment Tilikete C, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Hernández Martínez de Lapiscina E, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales A, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, Van Pesch V, Wang AG, Wattjes M, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT.
Lancet Neurol. 21 ( 12 ) 1120 - 1134 2022.12
-
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC on behalf of the N-MOmentum study investigators.
EBioMedicine. 86 104321 2022.12
-
Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Kissani N, Ouadika1 RJB, Kishk NA, Chaymae O, Ibrahim EAA, Maiga Y, Paul R, Daniel GM, Hamid A, Assogba K, Gaye NM, Hor JY, Tegueu CK, Marignier R, Palace J, Weinshenker BG, Ragab AH, Fujiharaa K. Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Open Access Library J. e9649 2022.9
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 269 ( 6 ) 3136 - 3146 2022.6
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022.5
-
Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series.
Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC, Hemingway C, Matsushima J, Sugaya N, Yamashita M, von Büdingen HC, Miyamoto K.
Mult Scler Relat Disord. 61 103772 2022.5
-
RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO.
4. Iwamoto S, Itokazu T, Sasaki A, Kataoka H, Tanaka S, Hirata T, Miwa K, Suenaga T, Takai Y, Misu T, Fujihara K, Yamashita T.
Ann Neurol. 91 ( 4 ) 532 - 547 2022.4
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022.3
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022.3
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022.3
-
AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
1. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk D, Green AJ, Fujihara K, Cutterj G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC, on behalf of the N-MOmentum study investigators.
Mult Scler Relat Disord 57 103356 2022.1
-
Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy.
Tanaka M, Fujihara K.
Clin Exp Neuroimmunol ( 13 ) 5 - 6 2022
-
Autoantibodies in central nervous system and neuromuscular autoimmune disorders A narrative review.
Joen MY, Seok JM, Fujihara K, Kim BJ.
Precis Future Med. 6 ( 2 ) 105 - 116 2022
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 2021.11
-
White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments.
Akaishi T. Misu T, Fujihara K. Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Takahashi T, Kuroda H, Fujimori J, Takai Y, Nishiayama S, Kaneko K, Ishii T, Aoki M, Nakashima I, Hozawa A.
Sci Rep. 11 ( 1 ) 22357 2021.11
-
GRP78 antibodies are associated with blood-brain barrier-breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder.
Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T.
Neurol Neuroimmunol Neuroinflamm. 9 ( 1 ) e1038 2021.11
-
Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life.
Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T. on behalf of The Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group.
J Neurol Sci. 428 117546 2021.9
-
MOG-antibody associated disease.
Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Dphil HA, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B.
Lancet Neurol. 20 ( 9 ) 762 - 772 2021.9
-
Five-year visual outcome after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I.
Mult Scler Relat Disord Mult Scler Relat Disord. 56 103222 2021.8
-
Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC.
Neurol Neuroimmunol Neuroinflamm. 8 ( 3 ) e978 2021.5
-
Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, Fujihara K, Itoyama Y, Aoki M.
Brain. 144 ( 8 ) 2401 - 2415 2021.5
-
Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.
Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I.
Neurology. 97 ( 1 ) e1 - e12 2021.5
-
Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report.
Asano T, Saito Y, Matsuoka N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima T, Fujihara K, Migita K.
Medicine (Baltimore). 100 ( 15 ) e24889 2021.4
-
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group.
Mult Scler Relat Disord. 50 ( 102849 ) 2021.2
-
Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Akaishi T, Himori N, Takeshita T, Fujihara K, Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, Nakashima I.
Brain Behav. 11 ( 5 ) e02083 2021.2
-
Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ, for the PREVENT Study Group.
Ann Neurol. 89 ( 6 ) 1088 - 1098 2021.2
-
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E.
Mult Scler. 27 ( 13 ) 2052 - 2061 2021.2
-
Progression pattern of neurological disability in reference to clinical attacks in anti-MOG antibody-associated disorders.
Akaish T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishi T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 31 ( 351 ) 577467 2021.2
-
Early Treatment Initiation with Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I.
Front Neurol 22 ( 12 ) 608149 2021.2
-
Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Nakashima I.
J Neurol 2021.1
-
CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.
Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M.
Heliyon 7 ( 1 ) e05899 - e05899 2021.1
-
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S, on behalf of the PREVENT Study Group.
Mult Scler Relat Disord ( 47 ) 102641 2021.1
-
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M.
Mult Scler Relat Disord 22 ( 49 ) 102750 2021.1
-
New therapies for neuromyelitis optica spectrum disorders.
Levy M, Fujihara K. Place J.
Lancet Neurol. 20 ( 1 ) 60 - 67 2021.1
-
Patterns of cortical grey matter thickness reduction in multiple sclerosis.
Fujimori, Fujihara K, Wattjes M, Nakashima I.
Brain Behav 27 e02050 2021.1
-
Treatment of MOG Antibody Associated Disorders: Results of an International Survey.
Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintz en RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A.
J Neurol 267 ( 12 ) 3565 - 3577 2020.12
-
Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
Akaishi T, Fujimori J, Takahashi T, Misu T, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 15 ( 349 ) 577431 2020.12
-
Distinctive lesions of bran MRI between MOG-antibody-associated and AQP4-antibody-associated diseases.
Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, Fujihara K, Aoki M.
J Neurol Neurosurg Psychiatry 92 ( 6 ) 2020.12
-
Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.
Akaishi T, Takshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, Fujihara K, Aoki M, Nakazawa T, Nakashima I.
Front Neurol 2 ( 11 ) 932 2020.9
-
Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders.
Akaishi T、Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, Aoki M, Fujihara K, Nakashima I.
Sci Rep 17 ( 10(1) ) 13890 2020.8
-
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D; Mughal T, Yamamura T.
Neurol Neuroimmunol Neuroinflamm 20 ( 7(5) ) e841 2020.8
-
Measurements of corpus callosum index and fractional anisotropy of the corpus callosum with their cutoffs are useful to comprehend global brain volume loss in multiple sclerosis.
Fujimori J, MD, Uryu K, Fujihara K, Wattjes MP, Suzuki C, Nakashima I.
Mult Scler Relat Disord 8 ( 45 ) 102388 2020.7
-
Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.
Akaishi T, Takahashi T, Fujihara K, Misu T, Nishiyama S, Takai Y, Fujimori J, Abe M, Ishii T, Aoki M, Nakashima I.
Mult Scler Relat Disord 7 ( 45 ) 102382 2020.7
-
Risk factors of attacks in neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Abe M, Ishii T, Aoki M, Nakashima I.
J Neuroimmunol 15 ( 343 ) 577236 2020.6
-
Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.
Whittam DH, Cobo-Calvo A, Chiriboga ASL, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin R, Mathey G, Laplaud D, Thouvenot F, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett J, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Anu Jacob A.
Mult Scler Relat Disord 2 ( 44 ) 102251 2020.6
-
Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K. Cook L.
Curr Opin Neurol 33 ( 3 ) 300 - 308 2020.6
-
Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K, with the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD.
Front Neurol 26 ( 11 ) 501 2020.6
-
Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
Akaishi T, Takahashi T, Fujihara K, Abe M, Ishii T, Aoki M, Nakashima I, Misu T, Mugikura S.
PLoS One 3 ( 15(4) ) e0231225 2020.4
-
Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.
Tsymala I, Nigritinou M, Zeka B, Schulz R, Niederschick F, Matković M, Bauer IJ, Szalay M, Schanda K, Lerch M, Misu T, Fujihara K, Bennett JL, Dahle C, Pache F, Rommer P, Leutmezer F, Illes Z, Leite MI, Palace J, Scholze P, Reindl M, Lassmann H, Bradl M.
Acta Neuropathol Commun 15 ( 8(1) ) 49 2020.4
-
Perivenous demyelination:association with anti-myelin oligodendrocyte glycoprotein.
Misu T, Takai Y, Takahashi T, Nakashima I, Fujihara K, Aoki M.
Clin Exp Neuroimmunol 11 ( Suppl. 1 ) 22 - 27 2020
-
MOG-IgG-associated disease.
Kaneko K, Takahahi T, Misu T, Nakashima I, Fujihara K.
Clin Exp Neuroimmunol 11 ( Suppl. 1 ) 28 - 33 2020
-
Trila of satralizumab in neuromyelitis optica spectrum disorder
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J
N Engl J 2019.11
-
Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy
Hino-Fukuyo N, Haginoya K, Takahashi T, Nakashima I, Fujihara K, Takai Y, Akasaka M, Kure S
Brain Dev 2019.10
-
Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease.
Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, Nakashima I
J Neuroimmunol 2019.6
-
Neuromyelitis optica spectrum disorders: still evolving and broadening
Fujihara K
Curr Opin Neurol 2019.6
-
治療法の再整理とアップデートのために 専門家による私の治療 急性散在脳脊髄炎（ADEM）
松本勇貴, 藤原一男
日本医事新報 ( 4964 ) 42 - 42 2019.6
-
【補体標的治療の現状と展望】視神経脊髄炎
黒田 宙、藤原 一男
BRAIN and NERVE: 神経研究の進歩 71 ( 6 ) 573 - 580 2019.6
-
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders: tools for clinical practice and drug trial design
Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ
Brain 2019.5
-
Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat.
Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M.
Acta Neuropathol 137 ( 3 ) 467 - 485 2019.3
-
Circulating AQP5-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M
Acta Neuropathol 2019.3
-
【視神経脊髄炎スペクトル障害（NMO-SD）】NMO-SDの疾患概念
三須 建郎、藤原 一男
脳神経内科 90 ( 1 ) 1 - 6 2019.1
-
Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation
Kuroda H, Nishiyama S, Matsumoto Y, Misu T, Fujihara K, Aoki M
Clin Exp Nuroimmunol 10 2019
-
Trial of eculizumab in aquaporin-4 positive neuromyelitis optica spectrum disorder
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM
N Engl J Med 2019
-
A randomised, placebo-controlled, double-blind trial of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: results of the N-MOmentum study
Cree B, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E
Lancet 2019
-
NMO spectrum and MOG-antibody-related disseminated encephalomyelitis
Misu T, Fujihara K
Clin Exp Neuroimmunol 2019
-
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.
Jurynczyk M, Jacob A, Fujihara K, Palace J.
Pract Neurol 2018.12
-
脱髄性疾患
北山通朗, 藤原一男
研修医が知っておきたい神経疾患の診断と治療 11 ( 10 ) 56 - 67 2018.12
-
視神経脊髄炎関連疾患と抗AQP4抗体 NMOSDの診断基準
松本勇貴, 藤原一男
Clinical Neuroscience,中枢神経系脱髄疾患-最前線抗MOG抗体の関与を考える 36 ( 11 ) 1306 - 1309 2018.11
-
MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung.
Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.
Nervenarzt 2018.9
-
虚血性心疾患によって発症した若年発症の両眼非動脈炎型虚血性視神経症の1例
小林奈美江, 小野田貴嗣, 小林健太郎, 永沼和香子, 藤原一男
臨床眼科 72 ( 9 ) 1241 - 1247 2018.9
-
多発性硬化症の創薬の展望
越智博文, 藤原一男
医薬ジャーナル, 神経難病と創薬 54 ( 7 ) 1661 - 1667 2018.7
-
神経脊髄炎 多発性硬化症との相違点
藤原一男
東京都医師会雑誌 71 ( 5 ) 384 - 388 2018.6
-
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.
J Neuroinflammation 3 ( 15(1) ) 134 2018.5
-
MOG-IgG-associated optic neuritis, encephalitis, and myelitis (MONEM): lessons learned from neuromyelitis optica spectrum disorder.
dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, Sato DK.
Front Neurol 2018.4
-
Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulins.
Matsumoto Y. Norshalena S, Tsuchiya M, Kaneko C, Kubo J, Yamamoto T, Takahashi T, Fujihara K.
Mult Scler J Exp Transl Clin. 9 ( 4(1) ) 2018.3
-
Myelin oligodendrocyte glycoprotein immunoglobulin G‐associated disease: An overview
Fujihara K, Sato DK, Nakashima I, Takahashi T, Kaneko K, Ogawa R, Akaishi T, Matsumoto Y, Takai Y, Nishiyama S, Kuroda H, Misu T, Aoki M.
Clin Exp Neuroimmunol 9 ( Suppl.1 ) 48 - 55 2018
-
Area Postrema Syndrome: Frequency, Criteria and Severity in AQP4-IgG positive NMOSD.
Shosha E, Dubey D, Palace J, Nakashima I, MD, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Takai Y, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.
Neurology 91 ( 17 ) e1642 - e1651 2018
-
CSF cytokine profile in MOG-IgG+neurologic disease is similar to AQP4-IgG+NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Yuji Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M.
J Neurol Neurosurg Psychiatry 89 927 - 936 2018
-
A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder.
Asato Y, Kamitani T, Ootsuka K, Kuramochi M, Nakanishi K, Shimada T, Takahashi T, Misu T, Aoki M, FujiharaK, Kawabata Y.
Intern Med 7 ( 20 ) 2981 - 2986 2018
-
A nationwide epidemiological study of neuromyelitis optica in Japan.
Miyamoto K, Fujihara K, Kira J, Kuriyama N, Matsui M, Tamakoshi A, Kusunoki S.
J Neurol Neurosurg Psychiatry 89 667 - 668 2018
-
Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.
Lancet Neurol 17 162 - 173 2018
-
Fingolimod-associated PML with mild IRIS in multiple sclerosis: a clinicopathological study.
Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R5, Watanabe M, Tominaga T, Nakashima I, Fujihara K, Aoki M.
Neurol Neuroimmunol Neuroinflamm 5 e415 2018
-
小児臨床検査のポイント2017】 自己抗体検査 臓器特異的自己抗体 神経疾患関連抗体 抗aquaporin-4(AQP4)抗体(解説/特集)
高橋利幸、藤原一男
小児内科 49 408 - 410 2017.11
-
Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A comparison of the Wechsler Adult Intelligence Scale-III and the Wechsler Memory Scale Revised with the Rao Brief Repeatable Neuropsychological Battery.
Fujimori J, Nakashima I, Baba T, Meguro Y, Ogawa R, Fujihara K.
eNeurologicalSci 21 ( 9 ) 3 - 7 2017.9
-
【NMOとMSの最新情報】 NMO(neuromyelitis optica)の最新の診断基準(解説/特集)
松本勇貴, 藤原一男
脊椎脊髄ジャーナル 30 ( 8 ) 736 - 741 2017.8
-
Differential diagnosis of neuromyelitis optica spectrum disorders.
Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K.
Ther Adv Neurol Disord 10 ( 7 ) 265 - 289 2017.7
-
Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies.
Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, Nishiyama S, Watanabe M, Tanji H, Kobayashi M, Misu T, Aoki M, Fujihara K
J Neurol Neurosurg Psychiatry 88 ( 6 ) 534 - 536 2017.6
-
第1章 左眼の奥が痛くて、物が見えづらいんです(左眼痛、左視力低下)
黒田宙, 藤原一男
内科「症候から考える画像診断アトラス」 119 578 - 581 2017.4
-
MOG-antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.
Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K
Neurol Neuroimmunol Neuroinflamm 4 ( 2 ) 322 - 322 2017.1
-
Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan.
Kanamori Y, Nakashima I, Takai Y, Misu T, Kuroda H, Nishiyama S, Takahashi T, Sato S, Fujimori J, Higuchi J, Itoyama Y, Aoki M, Fujihara K
J Neurol Neurosurg Psychiatry 88 362 - 364 2017
-
Practical issues and new horizons in MS, NMOSD and related disorders.
Fujihara K.
Clin Exp Neuroimmunol 8 1 - 2 2017
-
Neuromyelitis optica spectrum disorders.
Akaishi T, Nakashima I, Sato DK, Takahashi T, Fujihara K.
Neuroimaging Clin N Am 27 251 - 265 2017
-
Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
Akaishi T, Nakashima I, Mugikura S, Aoki M, Fujihara K.
J Neuroimmunol 306 68 - 75 2017
-
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.
Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HPB, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinshenker BG.
Neuro Neuroimmunol Neuroiflamm 4 e343 2017
-
Hypoxia-like tissue injury and glial response contribute to Balo’s concentric lesion development.
Takai Y, Misu T, Nishiyama S, Ono H, Kuroda H, Nakashima I, Saito R, Kanamori M, Sonoda Y, Kumabe T, Mugikura S, Watanabe M, Aoki M, Fujihara K
Neurology 87 ( 19 ) 2000 - 2005 2016.11
-
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD.
Zeka B, Hastermann M, Kaufmann N, Schanda K, Pende M, Misu T, Rommer P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl M, Lassmann H, Bradl M
Acta Neuropathol Commun 4 ( 1 ) 82 - 82 2016.8
-
Pseudo-perifascicular atrophy in the healing phase of Jo-1 antisynthetase syndrome.
Tateyama M, Shibuya S, Sato H, Fujihara K, Aoki M
Neuromuscul Disord 26 ( 8 ) 521 - 522 2016.8
-
Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO.
Higuchi O, Nakane S, Sakai W, Maeda Y, Niino M, Takahashi T, Fukazawa T, Kikuchi S, Fujihara K,Matuo H
Neurol Neuroimmunol Neuroinflamm 3 ( 5 ) 263 - 263 2016.7
-
Demyelinating diseases in Asia.
Ochi H, Fujihara K
Curr Opin Neurol 29 ( 3 ) 222 - 228 2016.6
-
Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem.
Adachi T, Yasui K, Takahashi T, Fujihara K, Watanabe Y, Nakashima K
Intern Med 55 ( 10 ) 1351 - 1354 2016.5
-
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Ogasawara M, Meguro A, Sakai T, Mizuki N, Takahashi T, Fujihara K, Tsuneoka H, Shikishima K
Jpn J Ophthalmol 60 ( 3 ) 198 - 205 2016.5
-
Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.
Oji S, Nicolussi EM, Kaufmann N, Zeka B, Schanda K, Fujihara K, Illes Z, Dahle C, Reindl M, Lassmann H, Bradl M
PLoS One 2016.3
-
Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, Takai Y, George J, Kitley J, Santos ME, Nour JM, Cheng F, Kuroda H, Misu T, Martins-da-Silva A, DeLuca GC, Vincent A, Palace J, Waters P, Fujihara K, Leite MI
Neurology 86 ( 1 ) 79 - 87 2016.1
-
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M
J Neurol Neurosurg Psychiatry 2016.1
-
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E
Mult Scledr 2016
-
MRI and retinal abnormalities in isolated optic neuritis with myelin-oligodendrocyte glycoprotein and aquaporin-4 antibodies
Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M
Journal of neurology, neurosurgery, and psychiatry 2016
-
The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients
Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N
Mult Scler 2016
-
Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica
Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida KI, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira JI
Mult Scler 2016
-
Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for non-responders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: implication for early institution of plasmapheresis.
Oji S, Tanaka S, Kojima M, Fukaura H, Mori M, Takahashi T, Fujihara K, Nomura K
Clin Exp Neuroimmunol 7 272 - 280 2016
-
The Binding Property of a Monoclonal Antibody Against the Extracellular Domains of Aquaporin-4 Directs Aquaporin-4 Toward Endocytosis.
Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y
Biochem Biophys Rep 7 77 - 83 2016
-
Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica.
Nishiyama S, Misu T, Nuriya M, Takano R, Takahashi T, Nakashima I, Yasui M, Itoyama Y, Aoki M, Fujihara K
Biochem Biophys Rep 7 45 - 51 2016
-
Experimental neuromyelitis optica induces a type I interferon signature in the spinal cord.
Oji S, Nicolussi E, Kaufmann N, Schanda K, Fujihara K, Illes Z, Reindl M, Lassmann H, Bradl M
PLoS ONE 11 ( 3 ) 2016
-
Lesion length of optic neuritis impacts visual prognosi in neuromyelitis optica.
Akaishi T, Ichiro Nakashima, Takeshita T, Mugikura S, Sato DK, Takahashi T, Nishiyama S, Kurosawa K, Misu T, Nakazawa T, Aoki M, Fujihara K
J Neuroimmunol 293 28 - 33 2016
-
Different etiologies and prognoses of optic neuritis in demyelinating diseases.
Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, Sato DK, Takahashi T, Nakazawa T, Aoki M, Fujihara K
J Neuroimmnol 299 152 - 157 2016
-
Serological markers associated with neuromyelitis optica spectrum disorders in South India.
Pandit L, Sato DK, Mustafa S, Takahashi T, D'Cunha A, Malli C, Sudhir A, Fujihara K
Ann Indian Acad Neurol 19 ( 4 ) 505 - 509 2016
-
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications".
Passos G, Sato D, Becker J, Fujihara K
Mediators Inflamm Mediators Inflamm 2016
-
High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.
Miyazaki-Komine K, Takai Y, Huang P, Kusano-Arai O, Iwanari H, Misu T, Koda K, Mitomo K, Sakihama T, Toyama Y, Fujihara K, Hamakubo T, Yasui M, Abe Y
Br J Pharmacol. 173 103 - 114 2016
-
The Binding Property of a Monoclonal Antibody Against the Extracellular Domains of Aquaporin-4 Directs Aquaporin-4 Toward Endocytosis.
Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y
Biochem Biophys Rep 7 77 - 83 2016
-
免疫性神経疾患-病態解明と治療の最前線:NMOの発症機序
小川 諒, 藤原一男
医学のあゆみ 2015
-
Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation
Tateyama M, Fujihara K, Misu T, Arai A, Kaneta T, Aoki M+L16L13:L17L13:L15
BMJ Open 2015
-
Importance of QAlb, QIgG, and Reibergram in inflammatory neurological disorders with disease-specific patterns of blood-brain barrier-permeability
Akaishi T, Narikawa K, Suzuki Y, Mitsuzawa S, Tsukita K, Kuroda H, Nakashima I, Fujihara K, Aoki M
Neurology and Clinical Neuroscience 2015
-
Spinal cord ring enhancement in patients with neuromyelitis optica
Yokote H, Nose Y, Ishibashi S, Kamata T, Tanaka K, Takahashi T, Fujihara K, Yokota T, Mizusawa H
Acta Neurol Scand 2015
-
Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report
Amano H, Miyamoto N, Shimura H, Sato D, Fujihara K, Ueno S, Nakamura R, Ueno Y, Watanabe M, Hattori N, Urabe T
BMC Neurol 2015
-
Acute callosal disconnection syndrome as an initial manifestation of neuromyelitis optica spectrum disorders
Kobayashi J, Kuroda H, Ezura M, Sugeno N, Shibui A, Takahashi T, Misu T, Fujihara K, Mori E, Aoki M
Neurology and Clinical Neuroscience 2015
-
The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model
Geis C, Ritter C, Ruschil C, Weishaupt A, Gr?newald B, Stoll G, Holmoy T, Misu T, Fujihara K, Hemmer B, Stadelmann C, Bennett JL, Sommer C, Toyka KV
Experimental Neurology 2015
-
Multiple Sclerosis in Japan appears to be a milder disease compared to the UK
Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, Ryan S, Cavey A, Fujihara K, Palace J
Journal of Neurology 2015
-
Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica
Kariya Y, Kariya Y, Saito T, Nishiyama S, Honda T, Tanaka K, Yoshida M, Fujihara K, Hashimoto Y
Biochimica et Biophysica Acta (BBA) Clinical 2015
-
Novel clinical grading of delayed neurologic sequelae after carbon monoxide poisoning and factors associated with outcome
Kuroda H, Fujihara K, Kushimoto S, Aoki M
Neurotoxicology 2015
-
Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies.
Hino-Fukuyo N, Kazuhiro Haginoya K, Nakashima I, Sato DK, Takahashi T, Misu T, Fujihara K, Hirose M, Kakisaka Y, Uematsu M, Kobayashi T, Shigeo Kure S
Brain Dev 2015
-
Comparison of the Rao Brief Repeatable Neuropsychological Battery with Wechsler Adult Intelligence Scale-III and Wechsler Memory Scale-Revised in Japanese patients with Multiple Sclerosis
Fujimori J, Baba T, Meguro Y, Nakashima I, Mori E, Fujihara K, Aoki M
Clinical and Experimental Neuroimmunology 2015
-
Depressive state and chronic fatigue in multiple sclerosis
Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M
Journal of Neurology 2015
-
MRI characteristics of neuromyelitis optica spectrum disorder
Kim, HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Jens Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH
Neurology 2015
-
Neuromyelitis optica and multiple sclerosis: Seeing differences through Optical Coherence Tomography
Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Klawiter EC, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul1 F
Mult Scledr 2015
-
Challenges and opportunities in designing clinical trials for neuromyelitis optica
Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree B, de Seze J, Armando Flor, Fujihara K, Greenberg BM, Higashi S, Holt W, Khan OA, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter SA, Villoslada P, Walton MK, Wasiewski W, Wingerchuk D, Yeaman M
Neurology 2015
-
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder
Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, St?ve O, Aktas O, Smith TJ, Jacob A, O'Connor KVilloslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; and the Guthy-Jackson Charitable Foundation
JAMA Neurology 2015
-
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG
Neurology 2015
-
視神経脊髄炎
金子仁彦、藤原一男
臨床雑誌内科 内科疾患の診断基準・病型分類・重症度 2015
-
神経・筋 多発性硬化症
金子仁彦、藤原一男
臨床雑誌内科 内科疾患の診断基準・病型分類・重症度 2015
-
AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS:Final answer ?
Fujihara K, Misu T
Neurology 2015
-
Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS
Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, Leutmezer F, Sato DK, Nakashima I, Reindl M, Lassmann H, Bradl M
Acta Neuropathologica 2015
-
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology
Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, Sato D, Fujihara K, Lassmann H, Schmutzhard E, Berger T
Neurol Neuroimmunol Neuroinflamm 2015
-
Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody
Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui M, Aoki M
Acta Neuropathologica Commun 2015
-
Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-positive optic neuritis with optic disc ischemia and macular star
Moura FC, Sato DK, Rimkus CM, Apostolos-Pereira SL, de Oliveira LM, Leite CC, Fujihara K, Monteiro MLR, Callegaro D
Neuro-Ophthalmology 2015
-
免疫症候群(第2版)-その他の免疫疾患を含めて-】 臓器特異的自己 免疫疾患 免疫性神経・筋疾患 免疫性中枢神経疾患 視神経脊髄炎
黒澤和大, 藤原一男
日本臨床:別冊免疫症候群I 2015
-
多発性硬化症(解説/特集)
藤盛寿一, 藤原一男
精神科:特集Ⅰ 免疫と精神神経疾患 2015